AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 11 analysts
Fundamentals
Fundamentals institutional score is 84 using growth durability 84.2.
Valuation
Valuation institutional score is 22 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 69 using mean target upside 10.9%; dispersion penalty 10.4; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 66 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 10 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. fundamentals and analyst consensus provide support, while valuation remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 48.2% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +1.47). Confidence: 68%.
Live forward EPS implies next-12-month EPS of ₹97.67. Applying the stock's normalized valuation corridor produces a fair range of ₹1,609.60 to ₹3,060.00, with base value near ₹2,361.66 (+4.9% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹97.67
Forward P/E
23.1x
Base Fair Value
₹2,361.66
Fair Range
₹1,609.60 - ₹3,060.00
Upside To Base
+4.9%
Estimate Source
Live forward EPS
Growth Estimate
+930.7%
5Y Average
18.11
Current
35.84
Overvalued
31.33
Undervalued
16.48
5Y Average
6.67
Current
13.03
Overvalued
10.02
Undervalued
2.85
5Y Average
1.83
Current
3.58
Overvalued
2.75
Undervalued
0.78
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
CIPLA LTD CIPLAPharmaceuticals | +3.5% | 12.0% | 35.2x Undervalued | -26% vs avg | -2.7% |
LUPIN LIMITED LUPINPharmaceuticals | +32.0% | 18.5% | 19.0x Undervalued | -60% vs avg | +21.5% |
TORRENT PHARMACEUTICALS L TORNTPHARMPharmaceuticals | +54.8% | 13.9% | 78.7x Premium | +66% vs avg | +36.2% |
MANKIND PHARMA LIMITED MANKINDPharmaceuticals | +12.9% | 13.9% | 49.4x Fair | +4% vs avg | +0.8% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 37.8x Undervalued | -20% vs avg | -15.6% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.6x Undervalued | -19% vs avg | +31.7% |
LAURUS LABS LIMITED LAURUSLABSPharmaceuticals | +29.1% | 15.0% | 91.4x Premium | +93% vs avg | +121.8% |
DR. REDDY S LABORATORIES DRREDDYPharmaceuticals | -5.6% | 10.0% | 29.2x Undervalued | -38% vs avg | -3.9% |
GLENMARK PHARMACEUTICALS trades at a discount (35.4x vs peer avg 47.4x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include CIPLA LTD, LUPIN LIMITED, TORRENT PHARMACEUTICALS L — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹2.44K CrJun 2026Latest net profit
₹736 CrJun 2026Latest EPS
₹26.07Jun 2026Net margin
25.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 2,144 | 2,233 | 1,365 | 2,148 | 2,330 | 2,636 | 2,251 | 2,010 | 2,395 | 1,539 | 2,360 | 2,147 | 2,435 |
| Expenses + | 1,659 | 1,790 | 1,549 | 1,651 | 1,698 | 1,857 | 1,757 | 1,669 | 1,667 | 1,717 | 1,864 | 2,115 | 1,822 |
| Operating Profit | 485 | 443 | -184 | 497 | 631 | 779 | 494 | 341 | 728 | -178 | 496 | 32 | 613 |
| OPM % | 23% | 20% | -14% | 23% | 27% | 30% | 22% | 17% | 30% | -12% | 21% | 1.5% | 25% |
| Other Income + | 18 | 54 | 234 | 5,933 | 56 | 83 | 129 | -91 | -254 | -646 | -68 | -61 | 338 |
| Interest | 62 | 58 | 74 | 83 | 15 | 12 | 8 | 13 | 15 | 23 | 22 | 18 | 23 |
| Depreciation | 49 | 50 | 51 | 52 | 53 | 55 | 55 | 56 | 58 | 59 | 59 | 60 | 62 |
| Profit before tax | 392 | 389 | -76 | 6,295 | 618 | 795 | 559 | 181 | 401 | -906 | 347 | -107 | 866 |
| Tax % | 31% | 22% | -73% | 27% | 27% | 25% | 26% | 18% | 18% | -18% | 19% | -31% | 15% |
| Net Profit + | 272 | 302 | -20 | 4,614 | 454 | 595 | 414 | 148 | 330 | -739 | 282 | -74 | 736 |
| EPS in Rs | 9.63 | 10.72 | -0.72 | 163.50 | 16.08 | 21.09 | 14.66 | 5.24 | 11.70 | -26.19 | 10.00 | -2.62 | 26.07 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Earnings Call Transcript